Current Opinion in Lipidology · 2007 · 198 citations · 40 references
Life SciencesBiochemistryPharmacologyCardiovascular PharmacotherapyInflammationLipid BiochemistryCardiovascular DiseaseCholesterol MetabolismLipid DisordersLipid MetabolismLipid-lowering TherapyLipoprotein MetabolismAtherosclerotic Cardiovascular Risk ReductionCardiovascular Risk ManagementOxidationPlasma Cholesterol LevelsProinflammatory MediatorsProtein Structural ChangesReverse Cholesterol TransportTherapeutic Lifestyle Change
PURPOSE OF REVIEW: This review addresses how, in atherosclerosis or systemic inflammation, HDL can lose its usual atheroprotective characteristics and even paradoxically assume proinflammatory properties. RECENT FINDINGS: Specific chemical and structural changes within HDL particles can impede reverse cholesterol transport, enhance oxidation of LDL, and increase vascular inflammation. HDL may be viewed as a shuttle that can be either anti-inflammatory or proinflammatory, depending on its cargo of proteins, enzymes, and lipids. Some therapeutic approaches that reduce coronary risk, such as statins and therapeutic lifestyle changes, can favorably moderate the characteristics of proinflammatory HDL. In addition, apolipoprotein A-I mimetic peptides and other compounds that target functional aspects of HDL may offer novel approaches to reduction in cardiovascular risk. SUMMARY: Current data suggest that under some conditions HDL can become dysfunctional and even proinflammatory, but this characterization can change with resolution of systemic inflammation or use of certain treatments.
40
S Manzi, Elaine N. Meilahn, Joan E. Rairie et al. · American Journal of Epidemiology · 1997 · 1.8K citations
Brian J. Van Lenten, Susan Hama, Frederick C. de Beer et al. · Journal of Clinical Investigation · 1995 · 832 citations · Full text
Mohamad Navab, S. Imes, Susan Hama et al. · Journal of Clinical Investigation · 1991 · 740 citations · Full text